Stuart E Lind

Title: Innovations of Stuart E Lind in Chimeric Proteins

Introduction

Stuart E Lind is an accomplished inventor based in Oklahoma City, OK (US). He has made significant contributions to the field of biotechnology, particularly in the development of chimeric proteins. With a total of 2 patents, his work focuses on innovative solutions for medical challenges.

Latest Patents

Lind's latest patents include the development of chimeric proteins with phosphatidylserine binding domains. These proteins comprise soluble Tissue Factor (sTF) and another subunit, such as annexin V. They are designed to promote blood clotting and inhibit cancer by targeting sTF to specific receptors like phosphatidylserine (PS) on activated cells. The applications of these chimeric proteins are vast, as they can treat patients suffering from excessive bleeding due to various conditions, including inborn problems, drug therapy, trauma, or surgery. Additionally, they serve as an anti-cancer therapy by causing blood vessels that feed tumors to become clotted, thereby restricting blood flow to the tumor and leading to its inhibition and potential death.

Career Highlights

Stuart E Lind is affiliated with the University of Oklahoma, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on both bleeding disorders and cancer treatment.

Collaborations

Lind collaborates with notable colleagues, including Wei-Qun Ding and Roger G Harrison, Jr. Their combined expertise contributes to the advancement of research in the field of chimeric proteins.

Conclusion

Stuart E Lind's innovative work in the development of chimeric proteins represents a significant advancement in medical science. His contributions have the potential to improve treatment options for patients facing serious health challenges.